Mavorixafor has 4 known drug interactions based on U.S. FDA drug labeling data. Of these, 1 are contraindicated combinations that should be avoided entirely. 2 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Cyp2d6 Substrates Highly Dependent On Cyp2d6 For Clearance, Cyp3a Inducers, Mao Inhibitors. Patients taking Mavorixafor should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.
- Total
- 4
- Contraindicated
- 1
- Major
- 2
- Moderate
- 1
Contraindicated (1)
- Mavorixafor + Cyp2d6 Substrates Highly Dependent On Cyp2d6 For Clearance— Concomitant use is contraindicated. Mavorixafor inhibits CYP2D6, increasing substrate exposure and risk of adverse react…
Major (2)
- Mavorixafor + Cyp3a Inducers— Concomitant use is contraindicated. Strong inducers decrease mavorixafor Cmax and AUC, reducing drug effectiveness.
- Mavorixafor + Mao Inhibitors— Concomitant use increases mavorixafor Cmax and AUC, increasing risk of adverse reactions. Requires dosage reduction to 2…
Moderate (1)
- Mavorixafor + P-Gp Or Bcrp Substrates— Increase mavorixafor Cmax and AUC. Monitor for adverse reactions and reduce dosage by 100 mg steps if necessary, but not…